Business
Embla Medical hf: Interim Report Q4 and Full Year 2025
Announcement no. 5/2026
About this update from Embla Medical Hf
COPENHAGEN, Denmark , Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025. Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish to the year, meanwhile sales in Bracing & Supports ended flat. The EBITDA margin came in at 19% compared to 21% in Q4 2024. The margin was positively impacted by strong sales growth and manufacturing efficiency but negatively impacted by FX, tariffs, and initiatives to enhance long-term growth and profitability in our Patient Care segment. Across markets, geographies, and patient care settings, 2025 was a year of meaningful progress for Embla Medical. The fundamental need for our solutions remains as strong as ever despite an increasingly uncertain geopolitical environment. For 2026 we are issuing new guidance of 5-8% organic sales growth and an EBITDA margin of 20-22%" Highlights Q4 2025 Other highlights 2026 Outlook *Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance. Q4 and Full Year 2025 Report The Interim Report for Q4 and full year 2025 is available on following link: Q4 and FY 2025 Report Conference call details Embla Medical will host a conference call on February 3, 2026, at 9:00 CET / 7:00 GMT / 3:00 ET . To actively participate in the telephone conference, please use the dial-in details provided below: DK: +45 78 76 84 90 UK: +44 20 3769 6819 US: +1 646 787 0157 Participant access code: 274982 The webcast will be available through following link: Embla Medical Q4/FY 2025 webcast Slides from the Q4/FY 2025 Conference Call is available here: Embla Medical Q4/FY 2025 Conf Call Updated investor road show presentation Our updated Q4/FY 2025 investor road show presentation can be downloaded on following link: Embla Medical Roadshow presentation Q4/FY 2025 Further information Klaus Sindahl, Head of Investor Relations, [email protected] , +45 5363 0134 Embla Medical press releases by e-mail If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors About Embla Medical Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. Embla Medical is home to several leading brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women's Empowerment Principles and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q4-and-full-year-2025,c4301524 The following files are available for download: View original content: https://www.prnewswire.com/news-releases/embla-medical-hf-interim-report-q4-and-full-year-2025-302677226.html